AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06193291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feet heating
Description: Feet placed in hot water
Study NCT06193291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calf heating
Description: Feet to calves placed in hot water
Study NCT03157401 — intervention group
Intervention type: DRUG
Intervention: control group
Description: In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Study NCT03356223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT00476346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium & Vitamin D
Description: Calcium 2000mg / daily Vitamin D 800IU / daily
Study NCT00476346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium & Vitamin D
Description: Calcium 2000mg / daily Vitamin D 800IU / daily
Study NCT02653508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Activity
Description: During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
Study NCT02653508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity
Description: All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
Study NCT02802995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP/thrombin mixture
Description: Mixture of platelet rich plasma and thrombin applied topically on the wound surface
Study NCT04085094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: high-salt diet (V1) and low salt diet (V2)
Description: Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
Study NCT04085094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced ultrasound (CEUS)
Description: Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
Study NCT04085094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
Study NCT04085094 — intervention group
Intervention type: OTHER
Intervention: Pilocarpine test
Description: Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
Study NCT03856866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine: 4mg/kg/day, divided bid.
Study NCT03856866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
Study NCT01384318 — intervention group
Intervention type: OTHER
Intervention: Manometer
Description: Measuring cuff pressure
Study NCT03116425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized rTMS on VERUM 1's region or network
Description: To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm.
Study NCT03116425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized rTMS on VERUM 2's region or network
Description: To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm.
Study NCT03116425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Individualized rTMS on PLACEBO region
Description: Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm.
Study NCT03116425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized rTMS on VERUM 1's region or network
Description: To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm.
Study NCT03116425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized rTMS on VERUM 2's region or network
Description: To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm.
Study NCT03116425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individualized rTMS on PLACEBO region
Description: Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm.
Study NCT02829697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perineural injection.
Study NCT02326727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Epidural analgesia
Study NCT02326727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: General Anesthesia
Study NCT02326727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General Anesthesia
Study NCT02326727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: General Anesthesia
Study NCT02326727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: General Anesthesia
Study NCT02719392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.
Study NCT02719392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
Study NCT02719392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
Study NCT02719392 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
Study NCT01929200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-year treatment with icotinib
Description: Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
Study NCT01929200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-year treatment with icotinib
Description: Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
Study NCT01406600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant hCG (Ovidrel®)
Description: Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
Study NCT01406600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant hCG (Ovidrel®)
Description: Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
Study NCT00400712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical rehabilitation
Description: two weeks intensive physical rehabilitation
Study NCT00067470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00067470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylgalactosamine 4-sulfatase
Study NCT00672360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
Study NCT00672360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
Study NCT00533429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
Study NCT00533429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
Study NCT03658408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine
Description: Oral tablet of 2.5 mg given 4 times a day
Study NCT03658408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2.5 mg sugar pill given orally 4 times a day
Study NCT00533429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
Study NCT04257071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.
Study NCT04257071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.
Study NCT04257071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OOP Cost Communication and Optimization
Description: OOP Cost Communication and Optimization includes personalized discussion of OOP cost estimates for treatment plan obtained through an online price transparency tool, personalized analysis of patients' expenses by financial counselor, and patient enrollment in any cost optimization opportunities for which patient is eligible using a comprehensive financial navigation program.
Study NCT03990649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablets
Study NCT03990649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soticlestat matching placebo tablets
Study NCT00973986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
Study NCT01808768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcaftadine
Description: Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
Study NCT01574859 — intervention group
Intervention type: OTHER
Intervention: levothyroxine
Description: titration of T4 according to biochemical values
Study NCT01611831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT in group
Description: A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
Study NCT01611831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improved treatment as usual by General Practitioners
Description: General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
Study NCT00540748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: 5 U i.v. during surgical abortion
Study NCT02582086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BOR15001L7
Description: Active cream with 5% 15019L0
Study NCT02582086 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Cream with 0% 15019L0
Study NCT03076125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCORRE
Description: 3 components based on the Health Belief Model
Study NCT03076125 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention-Control Activity
Description: sexual health education
Study NCT01539785 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary citoreduction
Description: The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
Study NCT01539785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intra-peritoneal chemotherapy (HIPEC)
Description: If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
Study NCT05816967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medication review and discharge counseling
Description: Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.
Study NCT00533429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Study NCT00533429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Study NCT04111172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
Description: Given as intramuscular injection
Study NCT03472599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genital Nerve Stimulation
Description: Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
Study NCT00533429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Study NCT02204514 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for external snapping hip
Study NCT02195817 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Selincro® 18 mg with continuous psychosocial support: Cohort A
Study NCT02195817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Initial psychosocial support: Cohort B
Study NCT00936117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: 200 mg (liquid) by mouth 3 times per day.
Study NCT00866515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole + GW642444M
Description: Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
Study NCT00866515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + GW642444M
Description: Placebo to match D1-6 + GW642444M 25ug single dose on D5
Study NCT00533429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: 15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
Study NCT00533429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily
Study NCT02072954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine Sublingual Tablets 10 mg
Description: White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
Study NCT02072954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asenapine Sublingual Tablets 10 mg
Description: Round, white to off-white sublingual tablets, with 10 on one side within a circle